Requiring institutions to inform participants who have completed therapy on SWOG-8892 (RT +/- cisplatin for nasopharyngeal cancer) about early study closure: right idea, wrong patients.

Subjects

Subjects :

Antineoplastic Agents therapeutic use
Carcinoma, Squamous Cell drug therapy
Carcinoma, Squamous Cell radiotherapy
Cisplatin therapeutic use
Clinical Trials, Phase III as Topic standards
Combined Modality Therapy
Humans
Multicenter Studies as Topic standards
Nasopharyngeal Neoplasms drug therapy
Nasopharyngeal Neoplasms radiotherapy
Patient Compliance
Professional Staff Committees standards
Radiation-Sensitizing Agents therapeutic use
United States
Carcinoma, Squamous Cell therapy
Clinical Trials, Phase III as Topic legislation & jurisprudence
Multicenter Studies as Topic legislation & jurisprudence
Nasopharyngeal Neoplasms therapy
Professional Staff Committees legislation & jurisprudence
Truth Disclosure

Details

Language :

English

ISSN :

0360-3016

Volume :

38

Issue :

3

Database :

MEDLINE

Journal :

International journal of radiation oncology, biology, physics

Publication Type :

Editorial & Opinion

Accession number :

9231694

Full Text :

https://doi.org/10.1016/s0360-3016(97)89491-6